ECSP055610A - Nuevo proceso para la síntesis de ivabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable - Google Patents

Nuevo proceso para la síntesis de ivabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable

Info

Publication number
ECSP055610A
ECSP055610A EC2005005610A ECSP055610A ECSP055610A EC SP055610 A ECSP055610 A EC SP055610A EC 2005005610 A EC2005005610 A EC 2005005610A EC SP055610 A ECSP055610 A EC SP055610A EC SP055610 A ECSP055610 A EC SP055610A
Authority
EC
Ecuador
Prior art keywords
ivabradine
synthesis
pharmaceutically acceptable
acceptable acid
same
Prior art date
Application number
EC2005005610A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Claude Souvie
Stephane Horvath
Jean-Michel Lerestif
Jean-Pierre Lecouve
Daniel Brigot
Auguste Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34941959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ECSP055610A publication Critical patent/ECSP055610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C11/00—Details of pavings
    • E01C11/16—Reinforcements
    • E01C11/165—Reinforcements particularly for bituminous or rubber- or plastic-bound pavings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
EC2005005610A 2004-04-13 2005-02-17 Nuevo proceso para la síntesis de ivabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable ECSP055610A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403830A FR2868777B1 (fr) 2004-04-13 2004-04-13 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
ECSP055610A true ECSP055610A (es) 2006-03-01

Family

ID=34941959

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005610A ECSP055610A (es) 2004-04-13 2005-02-17 Nuevo proceso para la síntesis de ivabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable

Country Status (43)

Country Link
US (2) US7176197B2 (https=)
EP (1) EP1589005B1 (https=)
JP (2) JP4515934B2 (https=)
KR (1) KR100677019B1 (https=)
CN (1) CN1305856C (https=)
AP (1) AP1821A (https=)
AR (1) AR047745A1 (https=)
AT (1) ATE358123T1 (https=)
AU (1) AU2005200861B2 (https=)
BR (1) BRPI0500585B8 (https=)
CA (1) CA2496723C (https=)
CO (1) CO5670092A1 (https=)
CR (2) CR7691A (https=)
CU (1) CU23465B7 (https=)
CY (1) CY1106597T1 (https=)
DE (1) DE602005000765T2 (https=)
DK (1) DK1589005T3 (https=)
EA (1) EA007745B1 (https=)
EC (1) ECSP055610A (https=)
ES (1) ES2285651T3 (https=)
FR (1) FR2868777B1 (https=)
GE (1) GEP20074138B (https=)
HK (1) HK1080362B (https=)
HR (1) HRP20070246T5 (https=)
IL (1) IL167013A (https=)
MA (1) MA27600A1 (https=)
ME (1) ME01396B (https=)
MX (1) MXPA05003694A (https=)
MY (1) MY141194A (https=)
NI (1) NI200500031A (https=)
NO (1) NO329807B1 (https=)
NZ (1) NZ538326A (https=)
OA (1) OA12913A (https=)
PL (1) PL1589005T3 (https=)
PT (1) PT1589005E (https=)
RS (1) RS50511B (https=)
SA (1) SA05260016B1 (https=)
SG (1) SG116575A1 (https=)
SI (1) SI1589005T1 (https=)
UA (1) UA80834C2 (https=)
UY (1) UY28759A1 (https=)
WO (1) WO2005110993A1 (https=)
ZA (1) ZA200501466B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
EP2460797A3 (en) * 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
WO2008125006A1 (fr) * 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
EP2162438A4 (en) * 2007-05-30 2011-07-06 Ind Swift Lab Ltd PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND CORRESPONDING POLYMORPHIDE
SI22750A (sl) * 2008-04-07 2009-10-31 Krka D.D. Ivabradin hidrobromid
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2933975B1 (fr) * 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
FR2935381B1 (fr) 2008-08-29 2010-12-17 Servier Lab Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine
CN101723897B (zh) * 2008-10-31 2011-11-16 齐鲁制药有限公司 伊伐布雷定的合成方法
ES2402765T3 (es) * 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
FR2940287B1 (fr) * 2008-12-24 2010-12-24 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
CN101768117B (zh) * 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101768116B (zh) * 2008-12-29 2014-06-18 北京德众万全药物技术开发有限公司 一种伊伐布雷定的制备方法
FR2941695B1 (fr) * 2009-02-04 2011-02-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ME00987B (me) * 2009-03-31 2012-06-20 Servier Lab Novi postupak sinteze ivabradina i njegovih soli sa farmaceutski prihvatljivom kiselinom
ME00986B (me) * 2009-03-31 2012-06-20 Servier Lab Novi postupak sinteze ivabradina i njegovih adicionih soli sa farmaceutski prihvatljivom kiselinom
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2534135A2 (en) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
FR2956401B1 (fr) * 2010-02-17 2012-02-03 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2011104723A2 (en) * 2010-02-23 2011-09-01 Ind-Swift Laboratories Limited Acid addition salts of ivabradine and preparation thereof
HUP1000245A2 (en) * 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
EP2579859B1 (en) 2010-06-14 2015-08-05 ratiopharm GmbH Solid ivabradine-containing composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
FR2971507B1 (fr) 2011-02-14 2013-01-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CN102304088B (zh) * 2011-07-07 2013-06-19 石药集团欧意药业有限公司 一种伊伐布雷定化合物、制备方法及其药物组合物
US9440924B2 (en) 2011-08-02 2016-09-13 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
FR2984319B1 (fr) * 2011-12-20 2013-12-27 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2984320B1 (fr) * 2011-12-20 2013-11-29 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2986804A1 (fr) * 2012-02-09 2013-08-16 Servier Lab Procede de synthese enzymatique de l'acide (7s) 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene 7-carboxylique ou de ses esters, et application a la synthese de l'ivabradine et de ses sels
FR2988720B1 (fr) * 2012-03-27 2014-03-14 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2993561B1 (fr) * 2012-07-17 2014-10-31 Servier Lab Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0]octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN103012268B (zh) * 2013-01-05 2015-02-25 江苏宇田生物医药科技有限公司 一种伊伐布雷定制备方法
EP2948432B1 (en) 2013-01-24 2018-09-19 Synthon BV Process for making ivabradine
ITMI20130684A1 (it) * 2013-04-24 2014-10-25 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
HRP20200300T4 (hr) 2013-03-19 2023-09-15 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida i metoda za njegovu pripremu
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
CN103864690B (zh) * 2014-01-06 2016-09-14 北京莱瑞森医药科技有限公司 伊伐布雷定盐酸盐的s晶型、其制备方法和药物组合物
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CN103880748B (zh) * 2014-04-03 2015-09-16 南京正大天晴制药有限公司 一种盐酸伊伐布雷定结构类似物及其制备方法和应用
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
EP3101010A1 (en) 2015-06-03 2016-12-07 Urquima S.A. New method for the preparation of highly pure ivabradine base and salts thereof
CN107056706B (zh) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 一种用于制备盐酸伊伐布雷定α晶型的方法
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (en) 2017-02-28 2025-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl
CN115286577B (zh) * 2022-08-25 2023-10-20 江苏永安制药有限公司 一种盐酸伊伐布雷定及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3519735A1 (de) * 1985-06-01 1986-12-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0204349A3 (de) * 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
FR2868776B1 (fr) * 2004-04-13 2008-04-18 Servier Lab Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
AU2005200861A1 (en) 2005-10-27
HK1080362B (zh) 2007-07-20
SG116575A1 (en) 2005-11-28
EA007745B1 (ru) 2006-12-29
BRPI0500585B1 (pt) 2020-11-03
CA2496723C (fr) 2010-05-25
MA27600A1 (fr) 2005-11-01
AU2005200861B2 (en) 2010-07-15
PT1589005E (pt) 2007-06-18
ZA200501466B (en) 2005-11-30
RS50511B (sr) 2010-03-02
UA80834C2 (en) 2007-11-12
BRPI0500585A (pt) 2005-11-16
HRP20070246T5 (en) 2008-10-31
NO329807B1 (no) 2010-12-20
IL167013A (en) 2011-08-31
WO2005110993A1 (fr) 2005-11-24
AP2005003222A0 (en) 2005-03-31
EP1589005B1 (fr) 2007-03-28
UY28759A1 (es) 2005-12-30
DK1589005T3 (da) 2007-07-30
CO5670092A1 (es) 2006-08-31
CR11780A (es) 2010-12-09
EP1589005A1 (fr) 2005-10-26
NO20050884L (no) 2005-10-14
SA05260016B1 (ar) 2009-06-06
CY1106597T1 (el) 2012-01-25
KR20060042116A (ko) 2006-05-12
HRP20070246T3 (en) 2007-08-31
PL1589005T3 (pl) 2007-07-31
CN1683341A (zh) 2005-10-19
CN1305856C (zh) 2007-03-21
KR100677019B1 (ko) 2007-02-01
ME01396B (me) 2010-03-02
HK1080362A1 (en) 2006-04-28
BRPI0500585B8 (pt) 2021-05-25
FR2868777B1 (fr) 2006-05-26
CU23465B7 (es) 2009-12-17
US7867994B2 (en) 2011-01-11
US20050228177A1 (en) 2005-10-13
ES2285651T3 (es) 2007-11-16
OA12913A (en) 2006-10-13
CR7691A (es) 2008-09-23
NI200500031A (es) 2006-05-25
JP2010047578A (ja) 2010-03-04
MY141194A (en) 2010-03-31
FR2868777A1 (fr) 2005-10-14
JP2005298480A (ja) 2005-10-27
US7176197B2 (en) 2007-02-13
DE602005000765T2 (de) 2008-01-10
DE602005000765D1 (de) 2007-05-10
JP4848449B2 (ja) 2011-12-28
NO20050884D0 (no) 2005-02-18
GEP20074138B (en) 2007-06-25
AP1821A (en) 2008-01-21
SI1589005T1 (sl) 2007-08-31
ATE358123T1 (de) 2007-04-15
NZ538326A (en) 2005-11-25
AR047745A1 (es) 2006-02-15
EA200500238A1 (ru) 2005-10-27
MXPA05003694A (es) 2006-01-24
JP4515934B2 (ja) 2010-08-04
CA2496723A1 (fr) 2005-10-13
US20070135411A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ECSP055610A (es) Nuevo proceso para la síntesis de ivabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
MXPA05005139A (es) Nuevo proceso para la sintesis de (1s)-4,5-dimetoxi-1-(metilaminometil)-benzociclobutano y sales de adicion del mismo, y aplicacion en la sintesis de ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.
SG162671A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
UY31883A (es) Nuevo procedimiento de síntesis de 7,8-dimetoxi-1, 3-dihidro-2h-3-benzazepin-2-ona, y aplicación en la síntesis de ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
MY156630A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO2781B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
JO2782B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
AR057885A1 (es) Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas.
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY160928A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
GT200600451A (es) Nuevo proceso para la síntesis de invabradina y sales de adición de la misma con un ácido farmacéuticamente aceptable
JO2518B1 (en) A new method for the combination of ivabradine and its added salts with pharmaceutically acceptable acid
SG165255A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid